Indivior Pharmaceuticals, Inc. (INDV) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Indivia PLC Q3 Results 2025 webcast and conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 and 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your host for today, Jason Thompson. Please go ahead. Thanks, Sharon, and welcome to Indivia's third quarter 2025 earnings conference call. I'm joined today by Joe Schifoni, Chief Executive Officer, Patrick Berry, Chief Commercial Officer, and Ryan Prebuck, Chief Financial Officer. We're also joined by Christian Heidretter, our Chief Scientific Officer, who is also available for questions. Before we begin, I need to remind everyone on today's call that we may make forward-looking statements that are subject to risks and uncertainties and that actual results may differ materially. We list the factors that may cause our results to be materially different on slide two of this presentation. We also may refer to non-GAAP measures, the reconciliations for which may also be found in the appendix to this presentation that is now posted on our website at endivir.com. I'll now turn the call over to Joe Schifoni, our CEO. Thanks, Jason. Good morning, and thank you for joining our third quarter results call. I'll start with a brief overview of our performance in the quarter and detail the progress we are making against the Indivier Action Agenda. Pat will then discuss Sublicate's performance and the progress we...